Medical Pharmacology Chapter 29 Diabetes Management Practice Questions

Dulaglutide (Trulicity):
1. Agonist at human glucagon -like peptide-1 (GLP-1) receptors.
2. Enhances glucose dependent insulin release
3. Increases gastric emptying
4. A & B
5. B & C
6. A & C
7. A, B & C
Dulaglutide (Trulicity):
1. Due to amino acid substitutions, dulaglutide is resistant to inactivation by dipeptidyl peptidase 4 (DPP-4)
2. Half-life of dulaglutide is about 12 hours
3. Both
4. Neither
Dulaglutide (Trulicity) may be administered as monotherapy or in combination with other agents.
1. True
2. False
Dulaglutide pharmacokinetics:
1. Bioavailability is about 50% (47%-65%)
2. Volume of distribution is about 18L.
3. Both
4. Neither
Dulaglutide half-life of elimination: about 5 days
1. True
2. False
Clinical indication for dulaglutide: In addition to diet and exercise, dulaglutide (Trulicity) assists glycemic management in adults diagnosed with type II diabetes mellitus.
1. True
2. False
Dulaglutide (Trulicity):
1. Contraindicated in individuals with either a personal or family history of medullary thyroid carcinoma (MTC)
2. Contraindicated in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
3. Both
4. Neither
Drugs other than dulaglutide (Trulicity) are likely recommended to treat diabetes mellitus in pregnancy (ADA 2020).
1. True
2. False
Most prominent adverse reaction following dulaglutide administration:
1. Cardiovascular
2. Gastrointestinal
3. Renal
4. Hepatic
5. Immunologic